{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:08:07Z","timestamp":1790388487485,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:00:00Z","timestamp":1542844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:00:00Z","timestamp":1542844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["134763"],"award-info":[{"award-number":["134763"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["151976"],"award-info":[{"award-number":["151976"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Collaborative Health Research Projects"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Amplification of HER2 leads to development of HER2-positive (HER2+) cancers with high rates of metastasis compared to other cancer subtypes. The goal of this study was to probe the vulnerability of HER2+ cancer cells to a filamentous actin (F-actin) severing and capping toxin. The growth and viability of human HER2+ breast cancer (HCC1954) and ovarian cancer (SKOV3) cell lines were significantly impaired upon treatment with the marine macrolide mycalolide B (Myc B) at doses above 100 nanomolar. Further testing of Myc B in combination with the antibody-drug conjugate Trastuzumab-emtansine (T-DM1) led to improved killing of SKOV3 cells compared to either treatment alone. At sub-lethal doses, treatment of HER2+ cancer cells with Myc B resulted in rapid loss of leading edge protrusions and formation of aggresomes containing F-actin and the actin regulatory protein Cortactin. This correlated with robust inhibition of HER2+ cancer cell motility and invasion with Myc B treatment. In SKOV3 tumor xenograft assays, intratumoral injections of Myc B impaired HER2+ tumor growth and metastasis, with maximal effects observed in combination with systemic delivery of Trastuzumab. Metastasis of SKOV3 cells to the lungs following tail vein injection was also reduced by Myc B. Together, these findings provide rationale for targeting F-actin in combination with existing therapies for HER2+ cancers to reduce metastasis.<\/jats:p>","DOI":"10.1038\/s41598-018-35284-9","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T10:51:51Z","timestamp":1542365511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effects of Modulating Actin Dynamics on HER2 Cancer Cell Motility and Metastasis"],"prefix":"10.1038","volume":"8","author":[{"given":"Sarah","family":"Nersesian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodette","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Newsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6609-5282","authenticated-orcid":false,"given":"P. Andrew","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Allingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2039-2393","authenticated-orcid":false,"given":"Andrew W.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,22]]},"reference":[{"key":"35284_CR1","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","volume":"26","author":"MM Moasser","year":"2007","unstructured":"Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469\u20136487, https:\/\/doi.org\/10.1038\/sj.onc.1210477 (2007).","journal-title":"Oncogene"},{"key":"35284_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182 (1987).","journal-title":"Science"},{"key":"35284_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-433","volume":"9","author":"JN McAlpine","year":"2009","unstructured":"McAlpine, J. N. et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 9, 433, https:\/\/doi.org\/10.1186\/1471-2407-9-433 (2009).","journal-title":"BMC Cancer"},{"key":"35284_CR4","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl, S. & Gianni, L. HER2-positive breast cancer. Lancet 389, 2415\u20132429, https:\/\/doi.org\/10.1016\/S0140-6736(16)32417-5 (2017).","journal-title":"Lancet"},{"issue":"Suppl 1","key":"35284_CR5","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1093\/annonc\/12.suppl_1.S81","volume":"12","author":"S Scholl","year":"2001","unstructured":"Scholl, S., Beuzeboc, P. & Pouillart, P. Targeting HER2 in other tumor types. Ann Oncol 12(Suppl 1), S81\u201387 (2001).","journal-title":"Ann Oncol"},{"key":"35284_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/0008-5472.CAN-16-1656","volume":"77","author":"KC Day","year":"2017","unstructured":"Day, K. C. et al. HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. Cancer Res 77, 74\u201385, https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1656 (2017).","journal-title":"Cancer Res"},{"issue":"12","key":"35284_CR7","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.3390\/ijms17122095","volume":"17","author":"Quanxia Lv","year":"2016","unstructured":"Lv, Q. et al. Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer. Int J Mol Sci 17, https:\/\/doi.org\/10.3390\/ijms17122095 (2016).","journal-title":"International Journal of Molecular Sciences"},{"key":"35284_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.breast.2016.07.026","volume":"29","author":"A Hernandez-Blanquisett","year":"2016","unstructured":"Hernandez-Blanquisett, A. et al. Current and emerging therapies of HER2-positive metastatic breast cancer. Breast 29, 170\u2013177, https:\/\/doi.org\/10.1016\/j.breast.2016.07.026 (2016).","journal-title":"Breast"},{"key":"35284_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-014-0201-0","volume":"74","author":"S Dhillon","year":"2014","unstructured":"Dhillon, S. Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy. Drugs 74, 675\u2013686, https:\/\/doi.org\/10.1007\/s40265-014-0201-0 (2014).","journal-title":"Drugs"},{"key":"35284_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3621","volume":"16","author":"M Barok","year":"2014","unstructured":"Barok, M., Joensuu, H. & Isola, J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 16, 209, https:\/\/doi.org\/10.1186\/bcr3621 (2014).","journal-title":"Breast Cancer Res"},{"key":"35284_CR11","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1126\/science.1164853","volume":"321","author":"CA Klein","year":"2008","unstructured":"Klein, C. A. Cancer. The metastasis cascade. Science 321, 1785\u20131787, https:\/\/doi.org\/10.1126\/science.1164853 (2008).","journal-title":"Science"},{"key":"35284_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nrc1886","volume":"6","author":"P Mehlen","year":"2006","unstructured":"Mehlen, P. & Puisieux, A. Metastasis: a question of life or death. Nat Rev Cancer 6, 449\u2013458, https:\/\/doi.org\/10.1038\/nrc1886 (2006).","journal-title":"Nat Rev Cancer"},{"key":"35284_CR13","doi-asserted-by":"publisher","first-page":"1740936","DOI":"10.1155\/2016\/1740936","volume":"2016","author":"W Chen","year":"2016","unstructured":"Chen, W., Dong, J., Haiech, J., Kilhoffer, M. C. & Zeniou, M. Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy. Stem Cells Int 2016, 1740936, https:\/\/doi.org\/10.1155\/2016\/1740936 (2016).","journal-title":"Stem Cells Int"},{"key":"35284_CR14","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1101\/gad.277681.116","volume":"30","author":"T Celia-Terrassa","year":"2016","unstructured":"Celia-Terrassa, T. & Kang, Y. Distinctive properties of metastasis-initiating cells. Genes Dev 30, 892\u2013908, https:\/\/doi.org\/10.1101\/gad.277681.116 (2016).","journal-title":"Genes Dev"},{"key":"35284_CR15","doi-asserted-by":"publisher","first-page":"e0119954","DOI":"10.1371\/journal.pone.0119954","volume":"10","author":"J Shankar","year":"2015","unstructured":"Shankar, J. & Nabi, I. R. Actin cytoskeleton regulation of epithelial mesenchymal transition in metastatic cancer cells. PLoS One 10, e0119954, https:\/\/doi.org\/10.1371\/journal.pone.0119954 (2015).","journal-title":"PLoS One"},{"key":"35284_CR16","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1111\/bph.12704","volume":"171","author":"CM Fife","year":"2014","unstructured":"Fife, C. M., McCarroll, J. A. & Kavallaris, M. Movers and shakers: cell cytoskeleton in cancer metastasis. Br J Pharmacol 171, 5507\u20135523, https:\/\/doi.org\/10.1111\/bph.12704 (2014).","journal-title":"Br J Pharmacol"},{"key":"35284_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0304-3835(97)00268-1","volume":"119","author":"R Iwazaki","year":"1997","unstructured":"Iwazaki, R. et al. The role of the cytoskeleton in migration and proliferation of a cultured human gastric cancer cell line using a new metastasis model. Cancer Lett 119, 191\u2013199 (1997).","journal-title":"Cancer Lett"},{"key":"35284_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2174\/1568009043332998","volume":"4","author":"J Rao","year":"2004","unstructured":"Rao, J. & Li, N. Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets 4, 345\u2013354 (2004).","journal-title":"Curr Cancer Drug Targets"},{"key":"35284_CR19","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s00018-006-6157-9","volume":"63","author":"JS Allingham","year":"2006","unstructured":"Allingham, J. S., Klenchin, V. A. & Rayment, I. Actin-targeting natural products: structures, properties and mechanisms of action. Cell Mol Life Sci 63, 2119\u20132134, https:\/\/doi.org\/10.1007\/s00018-006-6157-9 (2006).","journal-title":"Cell Mol Life Sci"},{"key":"35284_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1039\/c4np00129j","volume":"32","author":"M Kita","year":"2015","unstructured":"Kita, M. & Kigoshi, H. Marine natural products that interfere with multiple cytoskeletal protein interactions. Nat Prod Rep 32, 534\u2013542, https:\/\/doi.org\/10.1039\/c4np00129j (2015).","journal-title":"Nat Prod Rep"},{"key":"35284_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/(SICI)1097-0029(19991001)47:1<18::AID-JEMT3>3.0.CO;2-E","volume":"47","author":"I Spector","year":"1999","unstructured":"Spector, I., Braet, F., Shochet, N. R. & Bubb, M. R. New anti-actin drugs in the study of the organization and function of the actin cytoskeleton. Microsc Res Tech 47, 18\u201337, https:\/\/doi.org\/10.1002\/(SICI)1097-0029(19991001)47:1<18::AID-JEMT3>3.0.CO;2-E (1999).","journal-title":"Microsc Res Tech"},{"key":"35284_CR22","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.bmcl.2012.12.052","volume":"23","author":"O Ohno","year":"2013","unstructured":"Ohno, O. et al. Apoptosis-inducing activity of the actin-depolymerizing agent aplyronine A and its side-chain derivatives. Bioorg Med Chem Lett 23, 1467\u20131471, https:\/\/doi.org\/10.1016\/j.bmcl.2012.12.052 (2013).","journal-title":"Bioorg Med Chem Lett"},{"key":"35284_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrd2487","volume":"8","author":"TF Molinski","year":"2009","unstructured":"Molinski, T. F., Dalisay, D. S., Lievens, S. L. & Saludes, J. P. Drug development from marine natural products. Nat Rev Drug Discov 8, 69\u201385, https:\/\/doi.org\/10.1038\/nrd2487 (2009).","journal-title":"Nat Rev Drug Discov"},{"key":"35284_CR24","first-page":"453","volume":"10","author":"H Fujiki","year":"1989","unstructured":"Fujiki, H. et al. New Tumor Promoters from Marine Sources - the Okadaic Acid Class. Bioact Mol 10, 453\u2013460 (1989).","journal-title":"Bioact Mol"},{"key":"35284_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1021\/np960558d","volume":"60","author":"J Kobayashi","year":"1997","unstructured":"Kobayashi, J., Tsuda, M., Fuse, H., Sasaki, T. & Mikami, Y. Halishigamides A-D, new cytotoxic oxazole-containing metabolites from Okinawan sponge Halichondria sp. J Nat Prod 60, 150\u2013154, https:\/\/doi.org\/10.1021\/np960558d (1997).","journal-title":"J Nat Prod"},{"key":"35284_CR26","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1021\/ol300182r","volume":"14","author":"K Kobayashi","year":"2012","unstructured":"Kobayashi, K. et al. Design, synthesis, and biological evaluations of aplyronine A-mycalolide B hybrid compound. Org Lett 14, 1290\u20131293, https:\/\/doi.org\/10.1021\/ol300182r (2012).","journal-title":"Org Lett"},{"key":"35284_CR27","doi-asserted-by":"publisher","first-page":"7288","DOI":"10.1021\/ja101811x","volume":"132","author":"SA Rizvi","year":"2010","unstructured":"Rizvi, S. A. et al. Rationally simplified bistramide analog reversibly targets actin polymerization and inhibits cancer progression in vitro and in vivo. J Amer Chem Soc 132, 7288\u20137290, https:\/\/doi.org\/10.1021\/ja101811x (2010).","journal-title":"J Amer Chem Soc"},{"key":"35284_CR28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.chembiol.2008.01.010","volume":"15","author":"RD Perrins","year":"2008","unstructured":"Perrins, R. D., Cecere, G., Paterson, I. & Marriott, G. Synthetic mimetics of actin-binding macrolides: rational design of actin-targeted drugs. Chem Biol 15, 287\u2013294, https:\/\/doi.org\/10.1016\/j.chembiol.2008.01.010 (2008).","journal-title":"Chem Biol"},{"key":"35284_CR29","first-page":"511","volume":"5","author":"A Giganti","year":"2003","unstructured":"Giganti, A. & Friederich, E. The actin cytoskeleton as a therapeutic target: state of the art and future directions. Prog Cell Cycle Res 5, 511\u2013525 (2003).","journal-title":"Prog Cell Cycle Res"},{"key":"35284_CR30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2174\/1568026033452348","volume":"3","author":"G Fenteany","year":"2003","unstructured":"Fenteany, G. & Zhu, S. Small-molecule inhibitors of actin dynamics and cell motility. Curr Top Med Chem 3, 593\u2013616 (2003).","journal-title":"Curr Top Med Chem"},{"key":"35284_CR31","doi-asserted-by":"publisher","first-page":"e112542","DOI":"10.1371\/journal.pone.0112542","volume":"9","author":"MH Menhofer","year":"2014","unstructured":"Menhofer, M. H. et al. The actin targeting compound Chondramide inhibits breast cancer metastasis via reduction of cellular contractility. PLoS One 9, e112542, https:\/\/doi.org\/10.1371\/journal.pone.0112542 (2014).","journal-title":"PLoS One"},{"key":"35284_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep41252","volume":"7","author":"NI Zahaf","year":"2017","unstructured":"Zahaf, N. I. et al. Targeted delivery of an ADP-ribosylating bacterial toxin into cancer cells. Sci Rep 7, 41252, https:\/\/doi.org\/10.1038\/srep41252 (2017).","journal-title":"Sci Rep"},{"key":"35284_CR33","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.chembiol.2010.06.010","volume":"17","author":"JC Blain","year":"2010","unstructured":"Blain, J. C., Mok, Y. F., Kubanek, J. & Allingham, J. S. Two molecules of lobophorolide cooperate to stabilize an actin dimer using both their \u201cring\u201d and \u201ctail\u201d region. Chem Biol 17, 802\u2013807, https:\/\/doi.org\/10.1016\/j.chembiol.2010.06.010 (2010).","journal-title":"Chem Biol"},{"key":"35284_CR34","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1091\/mbc.E14-11-1564","volume":"26","author":"SL Cavolo","year":"2015","unstructured":"Cavolo, S. L. et al. Mycalolide B dissociates dynactin and abolishes retrograde axonal transport of dense-core vesicles. Mol Biol Cell 26, 2664\u20132672, https:\/\/doi.org\/10.1091\/mbc.E14-11-1564 (2015).","journal-title":"Mol Biol Cell"},{"key":"35284_CR35","doi-asserted-by":"crossref","first-page":"29710","DOI":"10.1016\/S0021-9258(18)43938-5","volume":"269","author":"S Saito","year":"1994","unstructured":"Saito, S., Watabe, S., Ozaki, H., Fusetani, N. & Karaki, H. Mycalolide B, a novel actin depolymerizing agent. J Biol Chem 269, 29710\u201329714 (1994).","journal-title":"J Biol Chem"},{"key":"35284_CR36","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/oxfordjournals.jbchem.a022029","volume":"123","author":"S Wada","year":"1998","unstructured":"Wada, S., Matsunaga, S., Saito, S., Fusetani, N. & Watabe, S. Actin-binding specificity of marine macrolide toxins, mycalolide B and kabiramide D. J Biochem 123, 946\u2013952 (1998).","journal-title":"J Biochem"},{"key":"35284_CR37","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1242\/jcs.017665","volume":"121","author":"F Lazaro-Dieguez","year":"2008","unstructured":"Lazaro-Dieguez, F. et al. Dynamics of an F-actin aggresome generated by the actin-stabilizing toxin jasplakinolide. J Cell Sci 121, 1415\u20131425, https:\/\/doi.org\/10.1242\/jcs.017665 (2008).","journal-title":"J Cell Sci"},{"key":"35284_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/oxfordjournals.jbchem.a021975","volume":"123","author":"SY Saito","year":"1998","unstructured":"Saito, S. Y. et al. Actin-depolymerizing effect of dimeric macrolides, bistheonellide A and swinholide A. J Biochem 123, 571\u2013578 (1998).","journal-title":"J Biochem"},{"key":"35284_CR39","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/S0040-4039(00)99131-7","volume":"30","author":"N Fusetani","year":"1989","unstructured":"Fusetani, N., Yasumuro, K., Matsunaga, S. & Hashimoto, K. Mycalolides-a - C, Hybrid Macrolides of Ulapualides and Halichondramide, from a Sponge of the Genus Mycale. Tetrahedron Lett 30, 2809\u20132812, https:\/\/doi.org\/10.1016\/S0040-4039(00)99131-7 (1989).","journal-title":"Tetrahedron Lett"},{"key":"35284_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1083\/jcb.201506002","volume":"211","author":"V Marchesin","year":"2015","unstructured":"Marchesin, V. et al. ARF6-JIP3\/4 regulate endosomal tubules for MT1-MMP exocytosis in cancer invasion. J Cell Biol 211, 339\u2013358, https:\/\/doi.org\/10.1083\/jcb.201506002 (2015).","journal-title":"J Cell Biol"},{"key":"35284_CR41","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1541-7786.MCR-08-0571","volume":"7","author":"NM Moss","year":"2009","unstructured":"Moss, N. M. et al. Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen. Mol Cancer Res 7, 809\u2013820, https:\/\/doi.org\/10.1158\/1541-7786.MCR-08-0571 (2009).","journal-title":"Mol Cancer Res"},{"key":"35284_CR42","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/sj.bjc.6603863","volume":"97","author":"KL Sodek","year":"2007","unstructured":"Sodek, K. L., Ringuette, M. J. & Brown, T. J. MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. Brit J Cancer 97, 358\u2013367, https:\/\/doi.org\/10.1038\/sj.bjc.6603863 (2007).","journal-title":"Brit J Cancer"},{"key":"35284_CR43","doi-asserted-by":"publisher","first-page":"13111","DOI":"10.1074\/jbc.M117.800904","volume":"292","author":"J Yang","year":"2017","unstructured":"Yang, J. et al. Post-translational modification of the membrane type 1 matrix metalloproteinase (MT1-MMP) cytoplasmic tail impacts ovarian cancer multicellular aggregate dynamics. J Biol Chem 292, 13111\u201313121, https:\/\/doi.org\/10.1074\/jbc.M117.800904 (2017).","journal-title":"J Biol Chem"},{"key":"35284_CR44","first-page":"2091","volume":"29","author":"H Konishi","year":"2009","unstructured":"Konishi, H. et al. Latrunculin A Has a Strong Anticancer Effect in a Peritoneal Dissemination Model of Human Gastric Cancer in Mice. Anticancer Res 29, 2091\u20132097 (2009).","journal-title":"Anticancer Res"},{"key":"35284_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/srep41434","volume":"7","author":"C Pergola","year":"2017","unstructured":"Pergola, C. et al. Modulation of actin dynamics as potential macrophage subtype-targeting anti-tumour strategy. Sci Rep 7, 41434, https:\/\/doi.org\/10.1038\/srep41434 (2017).","journal-title":"Sci Rep"},{"key":"35284_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1043\/2010-0454-RAR.1","volume":"135","author":"C Gutierrez","year":"2011","unstructured":"Gutierrez, C. & Schiff, R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135, 55\u201362, https:\/\/doi.org\/10.1043\/2010-0454-RAR.1 (2011).","journal-title":"Arch Pathol Lab Med"},{"key":"35284_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0900-z","volume":"19","author":"T Baldassarre","year":"2017","unstructured":"Baldassarre, T., Truesdell, P. & Craig, A. W. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. Breast Cancer Res 19, 110, https:\/\/doi.org\/10.1186\/s13058-017-0900-z (2017).","journal-title":"Breast Cancer Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35284-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35284-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35284-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T11:43:13Z","timestamp":1671622993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35284-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,22]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["35284"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-35284-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,22]]},"assertion":[{"value":"28 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"17243"}}